All Posts

PRESS RELEASE Lund, Sweden and Naples, Italy – November 28, 2018 New discoveries in cancer related immunosuppression are paving the way for an entirely new immunotherapeutic strategy. Cancer immunotherapy – the treatment approach that utilizes and enhances the power of…

CanImGuide Therapeutics AB, a private biopharmaceutical company based in Lund, Sweden, developing immunology therapeutics, announces that the clinical development of P28R, the company’s lead cancer drug, the first in a new class of immune-modulating drugs, has been initiated in Lund.…

The Nobel Prize in Medicine puts the spotlight on CanImGuide’s focus area Immunology. The Nobel Prize laureates have been awarded for the groundbreaking work in immunonucleology that led to the drugs called checkpoint inhibitors, which is used today successfully. Despite…

CanImGuide continues to develop successfully and is pleased to announce that Johan Drott has been engaged to lead the company into the next phase. Johan Drott has more than 20 years’ experience in life science companies. He is CEO of…